Recent Advances in Targeted Therapies for Cancer Treatment

Kartik Sitaram Bharad; Shital Tukaram Gaikwad; Badruddin Gaysuddin Khan; Shaikh Suleman A.R.; Gajanan Sanap

doi:10.55544/jrasb.4.1.2

Authors

Mr. Kartik Sitaram Bharad Department of Pharmaceutics, LBYP College of Pharmacy, Pathri, Phulambri, Chhatrapati Sambhajinager, Maharashtra, INDIA https://orcid.org/0009-0008-0759-1743
Mrs. Shital Tukaram Gaikwad Department of Pharmaceutics, LBYP College of Pharmacy, Pathri, Phulambri, Chhatrapati Sambhajinager, Maharashtra, INDIA
Mr. Badruddin Gaysuddin Khan Department of Pharmaceutics, LBYP College of Pharmacy, Pathri, Phulambri, Chhatrapati Sambhajinager, Maharashtra, INDIA
Mr. Shaikh Suleman A.R. Department of Pharmaceutics, LBYP College of Pharmacy, Pathri, Phulambri, Chhatrapati Sambhajinager, Maharashtra, INDIA
Dr. Gajanan Sanap Department of Pharmaceutics, LBYP College of Pharmacy, Pathri, Phulambri, Chhatrapati Sambhajinager, Maharashtra, INDIA.

DOI:

https://doi.org/10.55544/jrasb.4.1.2

Keywords:

Targeted cancer therapies, Precision oncology, Molecularly targeted drugs, Immunotherapy advancements

Abstract

Recent advances in understanding the birth mechanisms underpinning cancer development have driven the design of new remedial approaches, nominated ‘targeted curatives’, that widely intrude with motes or pathways involved in excrescence growth and progression. Inactivation of growth factors and their receptors on excrescence cells as well as the inhibition of oncogenic tyrosine kinase pathways and the inhibition of motes that control specific functions in cancer cells constitute the main rational bases of new cancer treatments acclimatized for individual cases. Small-patch impediments and monoclonal antibodies are major factors of these targeted approaches for a number of mortal malice. As the studies of the biomolecular features of cancer progress, new instigative strategies have arisen, similar as targeting cancer stem cells that drive excrescence relapses or the picky induction of apoptosis in nasty cells. This composition primarily focuses on the birth bases of the new cancer medicines and summarizes their mechanisms of action, the clinical substantiation of their anti-cancer effectiveness as well as the explanation for their use in clinical practice.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

References

Ciavarella S, Milano A, Dammacco F, Silvestris F. Targeted therapies in cancer. BioDrugs. 2010;24(2):77-88. doi:10.2165/11530830-000000000-00000

Reed JC. Dysregulation of apoptosis in cancer. J Clin Oncol. 1999;17(9):2941-2953. doi:10.1200/jco.1999.17.9.2941

Ionov Y, Yamamoto H, Krajewski S, Reed JC, Perucho M. Mutational inactivation of the proapoptotic gene BAX confers selective advantage during tumor clonal evolution. Proc Natl Acad Sci U S A. 2000;97(20):10872-10877. doi:10.1073/pnas.190210897

Holly TA, Drincic A, Byun Y, et al. Caspase inhibition reduces myocyte cell death induced by myocardial ischemia and reperfusion in vivo. J Mol Cell Cardiol. 1999;31(9):1709-1715. doi:10.1006/jmcc.1999.1006

Ranieri G, Patruno R, Ruggieri E, Montemurro S, Valerio P, Ribatti D. Vascular Endothelial Growth Factor (VEGF) as a Target of Bevacizumab in Cancer: From the Biology to the Clinic. Curr Med Chem. 2006;13(16):1845-1857. doi:10.2174/092986706777585059

Akhtar J, Wang Z, Zhang ZP, Bi MM. Lentiviral-mediated RNA interference targeting stathmin1 gene in human gastric cancer cells inhibits proliferation in vitro and tumor growth in vivo. J Transl Med. 2013;11(1):1-9. doi:10.1186/1479-5876-11-212

Silverman GJ. Anti-CD20 therapy and autoimmune disease: Therapeutic opportunities and evolving insights. Front Biosci. 2007;12(6):2194-2206. doi:10.2741/2222

Boner G, Cox AJ, Kelly DJ, et al. Does vascular endothelial growth factor (VEGF) play a role in the pathogenesis of minimal change disease? Nephrol Dial Transplant. 2003;18(11):2293-2299. doi:10.1093/ndt/gfg372

Feugier P, Van Hoof A, Sebban C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: A study by the groupe d’etude des lymphomes de l’adulte. J Clin Oncol. 2005;23(18):4117-4126. doi:10.1200/JCO.2005.09.131

Mendelsohn J, Baselga J. Epidermal Growth Factor Receptor Targeting in Cancer. Semin Oncol. 2006;33(4):369-385. doi: 10.1053/j.seminoncol.2006.04.003

Mohamed MK, Ramalingam S, Lin Y, Gooding W, Belani CP. Skin rash and good performance status predict improved survival with gefitinib in patients with advanced non-small cell lung cancer. Ann Oncol. 2005;16(5):780-785. doi:10.1093/annonc/mdi157

Park J, Park BB, Kim JY, et al. Gefitinib (ZD1839) monotherapy as a salvage regimen for previously treated advanced non-small cell lung cancer. Clin Cancer Res. 2004;10(13):4383-4388. doi:10.1158/1078-0432.CCR-04-0189

Agero ALC, Dusza SW, Benvenuto-Andrade C, Busam KJ, Myskowski P, Halpern AC. Dermatologic side effects associated with the epidermal growth factor receptor inhibitors. J Am Acad Dermatol. 2006;55(4):657-670. doi:10.1016/j.jaad.2005.10.010

Hidalgo BM, Siu LL, Nemunaitis J, et al. Jco.2001.19.13.3267 (1). 2019;19(13):3267-3279.

Cardones A, Banez L. VEGF Inhibitors in Cancer Therapy. Curr Pharm Des. 2005;12(3):387-394. doi:10.2174/138161206775201910

Johnson DH, Fehrenbacher L, Novotny WF, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol. 2004;22(11):2184-2191. doi:10.1200/JCO.2004.11.022

Hurwitz H, Saini S. Bevacizumab in the Treatment of Metastatic Colorectal Cancer: Safety Profile and Management of Adverse Events. Semin Oncol. 2006;33(SUPPL. 10):26-34. doi:10.1053/j.seminoncol.2006.08.001

Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, Mcguire WL. Correlation Amplification.

Bast J, Ravdin P, Hayes DF, et al. 2000 Update of recommendations for the use of tumor markers in breast and colorectal cancer: Clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol. 2001;19(6):1865-1878. doi:10.1200/jco.2001.19.6.1865

Pierre Amarenco, Julien Bogousslavsky, Alfred Callahan 3rd, Larry B Goldstein, Michael Hennerici, Amy E Rudolph, Henrik Sillesen, Lisa Simunovic, Michael Szarek, K M A Welch, Justin A Zivin SP by AR in CL (SPARCL) I. 需要引用的霍奇金第二肿瘤new England Journal. N Engl J Med. 2011;365:687-696.

Calvo E, Baselga J. Ethnic differences in response to epidermal growth factor receptor tyrosine kinase inhibitors. J Clin Oncol. 2006;24(14):2158-2163. doi:10.1200/JCO.2006.06.5961

Chung KY, Shia J, Kemeny NE, et al. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol. 2005;23(9):1803-1810. doi:10.1200/JCO.2005.08.037

Ross JS, Gray K, Gray GS, Worland PJ, Rolfe M. Anticancer antibodies. Am J Clin Pathol. 2003;119(4):472-485. doi:10.1309/Y6LPC0LR726L9DX9

Milenic D. Monoclonal Antibody-Based Therapy Strategies: Providing Options for the Cancer Patient. Curr Pharm Des. 2005;8(19):1749-1764. doi:10.2174/1381612023393963

Reilly RM, Sandhu J, Alvarez-Diez TM, Gallinger S, Kirsh J, Stern H. Problems of Delivery of Monoclonal Antibodies: Pharmaceutical and Pharmacokinetic Solutions. Clin Pharmacokinet. 1995;28(2):126-142. doi:10.2165/00003088-199528020-00004

Goldenberg DM. Targeted therapy of cancer with radiolabeled antibodies. J Nucl Med. 2002;43(5):693-713.

Ritchie M, Tchistiakova L, Scott N. Implications of receptor-mediated endocytosis and intracellular trafficking dynamics in the development of antibody drug conjugates. MAbs. 2013;5(1):13-21. doi:10.4161/mabs.22854.

Pranali Hatwar, Pallavi Dandge, Pravin Jagtap, Swapnil Gaikwad, Pranali Jadhav, Vaishnavi Sonawane and Dr. Gajanan Sanap. Formulation and Evaluation of solid perfume. World Journal of pharmaceutical. Volume 13, Issue 13,1338-1360.

Akash Haribhau Thengade, Rajeshwari K. Thokal and Gajanan S. Sanap. A REVIEW ON HYDROTROPY: A SOLUBILITY ENHANCING TECHNIQUE World Journal of Pharmaceutical Research SJIF Impact Factor 8.084. Volume 12, Issue 5, 1965-1978

Vaishnavi Mohanrao Sonawane, Pranali Hatwar and Dr. Gajanan Sanap. PROTEIN FIBER IN DRUG DELIVERY SYSTEM. World Journal of Pharmaceutical Research SJIF Impact Factor 8.084. Volume 12, Issue 22, 785-802.

Akash N. Thorat, Nakul P. Kathar, Dr. Gajanan S. Sanap and Manoj S. Bodkhe. REVIEW: BILAYER TABLET IS A NEW APPROACH. WORLD JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES. SJIF Impact Factor 7.632 Volume 12, Issue 5, 1028-1047

Ganesh Rajendera Badak, Shubhangi Manikpuriya and Dr. Gajanan S. Sanap. REVIEW: TRANSFEROSOMES: A VESICULAR TRANSDERMAL DELIVERY SYSTEM World Journal of Pharmaceutical Research SJIF Impact Factor 8.084 Volume 12, Issue 5, 2174-2187.

Mr. Vikas Bankar, Mr. Pratik Dhone, Mr. Shahrukh Sayyad, Ms. Nikita Khadke, Ms. Aditi Gawai, Mr. Suleman Shaikh and Dr. Gajanan Sanap. FORMULATION AND EVALUATION OF POLY HERBAL ANTI INFLAMMATORY Tablet WORLD JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES SJIF Impact Factor 8.025. Volume 13, Issue 7, 1057-1073

Abhijit Kumbhakar, Mr. Shaikh Suleman, Dr. Rana Zainuddin Ahmed, Mr. Kale Nitin. Topical Fibronectin Improves Wound Healing in Postmastectomy breast Cancer Radiation Therapy. International Journal of Scientific Research in Science and Technology